Positive Recommendation of IDMC Following Completion of Enrollment in REGAL Ph 3 Study Announced May 1, 2024
Ph 2 trial of VB10.16 with or without Tecentriq initiated for the treatment of HPV16+ve, PD-L1+ve, recurrent or metastatic cervical cancer May 1, 2024
First Cohort Completed and Second Cohort of Ph 1/2 Study of INKmune™ NK Cell Therapy in Patients with Metastatic CRPC Initiated May 1, 2024
Move-Forward Ph 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous NSCLC selected April 23, 2024
Successful Completion of Higher Dose Second Cohort in Ph 1/1b Trial of BP1002 in R/R AML Patients April 23, 2024
Clinical development of voruciclib to be advanced and new formulation of ME-344 to be enabled April 16, 2024
First Patient Dosed in First-in-Human Ph 1/2 Trial of BBI-825 in Patients with Resistance Gene Amplifications April 16, 2024
REJOICE-Ovarian01 Ph 2/3 Trial of Raludotatug Deruxtecan Initiated in Platinum-Resistant Ovarian Cancer April 9, 2024
Ph 3 Trial of MK-1084 + KEYTRUDA for 1L Treatment of Certain Patients With Metastatic NSCLC initiated April 9, 2024
Alliance A032103 (MODERN) Randomized, Ph 2/3 Adjuvant Trial in Urothelial Cancer announced April 9, 2024
Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL April 9, 2024
Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML April 2, 2024
Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML April 2, 2024
First Participant dosed in Ph 3 Study (Neoshot) of IBI310 + Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy April 2, 2024
First Patient Dosed in Ph 1/2a Trial of IMM-6-415 in Advanced Solid Tumors with RAF/RAS Mutations April 2, 2024
First Patient Dosed in Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C+ve Solid Tumors April 2, 2024
Enrollment of 190 Patients to Support Primary Endpoint Analysis in SELECT-MDS-1 Ph 3 Trial completed April 2, 2024
